Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey.
Barnaby F FlowerJonathan C BrownBryony SimmonsMaya MosheRebecca FriseRebecca PennRuthiran KugathasanClaire PetersenAnna DauntDeborah AshbySteven RileyChristina Joanne AtchisonGraham P TaylorSutha SatkunarajahLenny NaarRobert KlaberAnjna BadhanCarolina RosadasMaryam KhanNatalia FernandezMacià Sureda-VivesHannah M CheesemanJessica O'HaraGianluca FontanaScott John Charles PallettMichael RaymentRachael JonesLuke Stephen Prockter MooreMyra O McClurePeter CherepanovRichard TedderHutan AshrafianRobin ShattockHelen WardAra DarziPaul ElliotWendy S BarclayGraham S CookePublished in: Thorax (2020)
LFIA sensitivity and sample concordance is variable, highlighting the importance of evaluations in setting of intended use. This rigorous approach to LFIA evaluation identified a test with high specificity (98.6% (95%CI 97.1% to 99.4%)), moderate sensitivity (84.4% with finger prick (95% CI 70.5% to 93.5%)) and moderate concordance, suitable for seroprevalence surveys.